PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

o.s. Patent and Trademark Office: 0.s. DEPARTMENT OF Commence

Once the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Co	mplete if Known		
Application Number	10/074,974		
Filing Date	2/13/2002	-	
First Named Inventor	Pinnell	5	
Group Art Unit	1674/654		
Examiner Name	PATTEN	2	
Attomey Docket Number	Skic001	8	

	U.S. PATENT DOCUMENTS (Lass Subclas)							
Examiner Initials*	Cite No.1	U.S. Patent Document Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
PP	AΑ	546645		Huffstutler, Jr	11/14/95			
PO		5496553		Wilson et al	3/5/96			
PP	A.C.	6358542	2	Cuomo et al	3/19/02			
	11.5							
					ļ			
	├—	<u> </u>						
	├							
		 						
								
	·				1			
				•				
					ļ			
	ļ	<u> </u>	_					
	1	I			l			

				FORE	IGN PATENT DOCUMEN	TS		
C	Cita		oreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number 4	Kind Code [†] (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	76
								igspace
								\bot
	<u> </u>	 -				 		1-
ļ	<u> </u>			···				+
		 		- i - i		 		1
		1 1		1				
								\bot
	l							

Examiner Signature Status Satte	Date Considered 7/9/62

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/088 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Compl te if Known				
Application Number	10/074,974	<u> </u>		
Filing Date	2/13/2002			
First Named Inventor	Pinnell	5		
Group Art Unit	1614 1654	7		
Examiner Name	PANTEN	2		
Attorney Docket Number	SKICOO1			

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
PP	ВА	HANBURY, On the febrifuge properties of the olive (Olea europaea L.), unknown publication information Pharmaceutical Journal of Provincial Transactions pp.353-354	. #
7	ВВ	SHASHA, On the oleuropein, the bitter principle of olives, Vol. 26:1948-1954, 1960.	a Å, *
	ВС	REDMAN, In vivo antiviral chemotherapy, Antimi-crobial Agents & Chemotherapy 1966, 497-502.	
		FLEMING, Isolation of a bacterial inhibitor from green olives, Appl. Micro. 18:856-860, 1969,	
V	1 1	PETKOV, Pharmacological analysis of the iridoid; oleuropein, anrneimForsch (Drug Res.) 22:1476-86	
PP	BF	FLEMING, Antimicrobial properties of oleuropein and products of its hydrolysis from green olives, Appl. Micro. 26:777-782. 1973-	
eleti	вс		a I
ρρ	l at	BENAVENTE-GARCIA, Antioxidant activity of phenolics extracted from Olea europaea L. leaves, Food Chem.	
		:457-462, 2000.	
<u>. </u>			
		<u> </u>	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.